Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study

Ailiana Santosa1, Stefan Franzén2,3, Jonatan Nåtman3

  • 1School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. ailiana.santosa@gu.se.

Scientific Reports
|July 14, 2022
PubMed

Insights

Statin use in individuals aged 40 and over was associated with a reduced risk of COVID-19 hospitalization and death. This protective effect was observed across the general population and specific COVID-19 patient cohorts.

Area of Science:

  • Epidemiology
  • Pharmacology

Background:

  • The relationship between statin use and COVID-19 outcomes is not fully understood.
  • Statins are widely prescribed lipid-lowering medications with potential anti-inflammatory properties.

Purpose of the Study:

  • To investigate the association between statin exposure and the risk and severity of COVID-19.
  • To analyze these effects in the general population and in defined COVID-19 patient cohorts.

Main Methods:

  • Utilized nationwide Swedish population-based register data, including the National Prescribed Drug Register and COVID-19 outcome registers.
  • A cohort of individuals aged ≥40 years was selected, with statin exposure defined as prescriptions in the year prior to the index date.
  • Cox regression with propensity score Average Treatment effect in the Treated (ATT) weighting was employed to control for confounding.

Main Results:

  • Among 572,695 individuals, 22.3% were prior statin users.
  • Statin users showed a reduced risk of hospitalization and COVID-19 death in the overall and onset cohorts after ATT weighting.
  • In the hospitalized cohort, statin use was linked to lower mortality (HR=0.86) but not ICU admission.

Conclusions:

  • Statin-treated individuals demonstrated lower COVID-19 mortality compared to non-users.
  • Findings suggest a potential protective role of statins against severe COVID-19 outcomes, including death.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
852
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
113
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
662
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15